Serdexmethylphenidate

Summary

Serdexmethylphenidate (CHEMBL4301162) is an approved small molecule; indicated across 1 condition including idiopathic hypersomnia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 500.5 Da · C25H30N3O8+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4301162
Name	Serdexmethylphenidate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	134823896
Molecular formula	C25H30N3O8+
Molecular weight	500.5
InChIKey	UBZPNQRBUOBBLN-PWRODBHTSA-O

SMILES: COC(=O)[C@@H]([C@H]1CCCCN1C(=O)OC[N+]2=CC=CC(=C2)C(=O)N[C@@H](CO)C(=O)O)C3=CC=CC=C3

IUPAC name: (2S)-3-hydroxy-2-[[1-[[(2R)-2-[(1R)-2-methoxy-2-oxo-1-phenylethyl]piperidine-1-carbonyl]oxymethyl]pyridin-1-ium-3-carbonyl]amino]propanoic acid

Also known as: KP-415 INNER SALT, Serdexmethylphenidate, Serdexmetilfenidato, SERDEXMETHYLPHENIDATE

Parent form; salt/anhydrous children: CHEMBL4298139

Patent coverage: 4 distinct patent families (17 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
idiopathic hypersomnia	2	MONDO:0018044	MONDO:0018044

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06000501	PHASE4	COMPLETED	Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening
NCT05668754	PHASE2	COMPLETED	Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).